Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Licenses Genetic Profile for Tamoxifen Resistance from Erasmus Medical Center

NEW YORK (GenomeWeb News) - Agendia said today that it has signed a license agreement with the Erasmus University Medical Center in Rotterdam, the Netherlands, giving it exclusive rights to a genetic profile that predicts resistance to tamoxifen.
 
Agendia said it will validate the tamoxifen profile in collaboration with the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital.
 
Once validated, the company intends to add the profile to its MammaPrint gene expression-based breast cancer recurrence test.
 
In addition to the license agreement, the three organizations have entered a research collaboration focused on "next-generation hormonal therapies for breast cancer," Agendia said.
 
Financial terms of the agreement were not disclosed.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.